Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.

Eun Joo KangMyung-Ju AhnChan-Young OckKeun-Wook LeeJung Hye KwonYaewon YangYoon Hee ChoiMin Kyoung KimJun Ho JiTak YunByung-Ho NamSung-Bae Kim Bhumsuk Keam

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

In this first randomized trial in patients with ACC, axitinib significantly increased the 6-month PFS rate as compared with observation. (ClinicalTrials.gov number, NCT02859012).

Keyphrases

phase ii study
open label
placebo controlled
metastatic renal cell carcinoma
double blind
phase iii
phase ii
locally advanced
squamous cell carcinoma
small cell lung cancer
clinical trial
study protocol
randomized controlled trial
radiation therapy